327 related articles for article (PubMed ID: 33764483)
21. Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma.
Bondoc A; Glaser K; Jin K; Lake C; Cairo S; Geller J; Tiao G; Aronow B
Commun Biol; 2021 Sep; 4(1):1049. PubMed ID: 34497364
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of
Beck A; Trippel F; Wagner A; Joppien S; Felle M; Vokuhl C; Schwarzmayr T; Strom TM; von Schweinitz D; Längst G; Kappler R
Clin Epigenetics; 2018; 10():27. PubMed ID: 29507645
[TBL] [Abstract][Full Text] [Related]
23. A novel tissue-based ß-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors.
Dubbink HJ; Hollink IHIM; Avenca Valente C; Wang W; Liu P; Doukas M; van Noesel MM; Dinjens WNM; Wagner A; Smits R
Pediatr Blood Cancer; 2018 Jun; 65(6):e26991. PubMed ID: 29446530
[TBL] [Abstract][Full Text] [Related]
24. KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants.
Ke B; Shen XD; Zhang Y; Ji H; Gao F; Yue S; Kamo N; Zhai Y; Yamamoto M; Busuttil RW; Kupiec-Weglinski JW
J Hepatol; 2013 Dec; 59(6):1200-7. PubMed ID: 23867319
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial fragmentation is crucial for c-Myc-driven hepatoblastoma-like liver tumors.
Wang D; Tian J; Yan Z; Yuan Q; Wu D; Liu X; Yang S; Guo S; Wang J; Yang Y; Xing J; An J; Huang Q
Mol Ther; 2022 Apr; 30(4):1645-1660. PubMed ID: 35085814
[TBL] [Abstract][Full Text] [Related]
26. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.
Buendia MA
Med Pediatr Oncol; 2002 Nov; 39(5):530-5. PubMed ID: 12228912
[TBL] [Abstract][Full Text] [Related]
27. Intracellular localization of beta-catenin expression plays a possible prognostic role on the outcome of hepatoblastoma patients.
Celtik U; Dokumcu Z; Divarci E; Guler E; Ataseven E; Nart D; Yilmaz F; Celik A; Ergün O
Pediatr Surg Int; 2020 Jul; 36(7):817-825. PubMed ID: 32436062
[TBL] [Abstract][Full Text] [Related]
28. USP7 promotes hepatoblastoma progression through activation of PI3K/AKT signaling pathway.
Ye M; He J; Zhang J; Liu B; Liu X; Xie L; Wei M; Dong R; Li K; Ma D; Dong K
Cancer Biomark; 2021; 31(2):107-117. PubMed ID: 33780361
[TBL] [Abstract][Full Text] [Related]
29. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
30. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
Wei Y; Fabre M; Branchereau S; Gauthier F; Perilongo G; Buendia MA
Oncogene; 2000 Jan; 19(4):498-504. PubMed ID: 10698519
[TBL] [Abstract][Full Text] [Related]
31. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas.
Yamada S; Ohira M; Horie H; Ando K; Takayasu H; Suzuki Y; Sugano S; Hirata T; Goto T; Matsunaga T; Hiyama E; Hayashi Y; Ando H; Suita S; Kaneko M; Sasaki F; Hashizume K; Ohnuma N; Nakagawara A
Oncogene; 2004 Aug; 23(35):5901-11. PubMed ID: 15221005
[TBL] [Abstract][Full Text] [Related]
32. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome.
Weber RG; Pietsch T; von Schweinitz D; Lichter P
Am J Pathol; 2000 Aug; 157(2):571-8. PubMed ID: 10934159
[TBL] [Abstract][Full Text] [Related]
33. CDK9 is dispensable for YAP-driven hepatoblastoma development.
Chen X; Kiss A; Schaff Z; Evert K; Zhang Y; Zhong S; Wang J; Evert M; Calvisi DF; Chen X
Pediatr Blood Cancer; 2020 May; 67(5):e28221. PubMed ID: 32124532
[TBL] [Abstract][Full Text] [Related]
34. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model.
Warmann S; Hunger M; Teichmann B; Flemming P; Gratz KF; Fuchs J
Cancer; 2002 Oct; 95(8):1795-801. PubMed ID: 12365029
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Ellerkamp V; Lieber J; Nagel C; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):141-9. PubMed ID: 23266718
[TBL] [Abstract][Full Text] [Related]
36. Novel Advances in Understanding of Molecular Pathogenesis of Hepatoblastoma: A Wnt/β-Catenin Perspective.
Bell D; Ranganathan S; Tao J; Monga SP
Gene Expr; 2017 Feb; 17(2):141-154. PubMed ID: 27938502
[TBL] [Abstract][Full Text] [Related]
37. The occurrence of liver growth factor in hepatoblastoma.
von Schweinitz D; Fuchs J; Glüer S; Pietsch T
Eur J Pediatr Surg; 1998 Jun; 8(3):133-6. PubMed ID: 9676393
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94.
Fuchs J; Rydzynski J; Von Schweinitz D; Bode U; Hecker H; Weinel P; Bürger D; Harms D; Erttmann R; Oldhafer K; Mildenberger H;
Cancer; 2002 Jul; 95(1):172-82. PubMed ID: 12115331
[TBL] [Abstract][Full Text] [Related]
39. Targeting autophagy to modulate hepatic ischemia/reperfusion injury: A comparative study between octreotide and melatonin as autophagy modulators through AMPK/PI3K/AKT/mTOR/ULK1 and Keap1/Nrf2 signaling pathways in rats.
Mohamed DZ; El-Sisi AEE; Sokar SS; Shebl AM; Abu-Risha SE
Eur J Pharmacol; 2021 Apr; 897():173920. PubMed ID: 33571535
[TBL] [Abstract][Full Text] [Related]
40. Synergistic Carcinogenesis of HPV18 and MNNG in Het-1A Cells through p62-KEAP1-NRF2 and PI3K/AKT/mTOR Pathway.
Zhang Y; Ma Y; Zhao C; Zhang H; Pu Y; Yin L
Oxid Med Cell Longev; 2020; 2020():6352876. PubMed ID: 33123313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
